Marksans Pharma Q2 FY27: PAT ₹159 Cr & Rev ₹841 Cr

Metric	Value
Revenue	₹841 Cr
Net Profit (PAT)	₹159 Cr

📢 Key Event
Record Q1FY27 profitability with revenue, EBITDA, PAT, and cash balance growth

🔄 What Changed
Revenue +35.6% YoY, EBITDA +112.8% YoY, PAT +173.9% YoY, cash balance ₹1,058 crore

🔮 What's Next
Scale businesses across geographies, accelerate new launches, strengthen European platform

💡 Investor Takeaway
Strong European growth and cash position support sustainable expansion and margin improvement

Marksans Pharma reported record Q1FY27 results with operating revenue of ₹841 crore, up 35.6% YoY, driven by strong UK/Europe growth of 74.7% YoY to ₹356 crore. EBITDA surged 112.8% to ₹213 crore, PAT rose 173.9% to ₹159 crore, and cash balance crossed ₹1,000 crore to ₹1,058 crore. The company highlighted European expansion via QliniQ acquisition and improved working capital cycle to 132 days.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MARKSANS ✨ Ask AI About This

About Marksans Pharma Limited (MARKSANS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,612.26 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

💡 Ask AI about this filing

"How does QliniQ acquisition impact long-term European margins?" "What is the target for European revenue contribution by FY28?" "How will cash balance be deployed for acquisitions or R&D?"

Ask AI Free →

📊 More MARKSANS filings

See all MARKSANS filings →

🔥 Also filed on 12 August 2026

DBL Dilip Buildcon Limited Corporate Action NITCO Nitco Limited Financial Results KPIGREEN KPI Green Energy Limited Financial Results SDBL Som Distilleries & Breweries Limited Financial Results CONSOFINVT Consolidated Finvest & Holdings Limited Corporate Action TOUCHWOOD Touchwood Entertainment Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd